Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.40 |
| ▸ | MAOB | P27338 | 8/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1516003 | 1.00 | MAPT (0.46) | MAPTTP53HPGDTSHRMEN1 | |
| SCHEMBL3148487 | 0.89 | TP53 (0.45) | MAPTTP53HPGDTSHRMEN1 | |
| SCHEMBL3142942 | 0.89 | TP53 (0.45) | MAPTTP53HPGDTSHRMEN1 | |
| SCHEMBL3142952 | 0.89 | TP53 (0.45) | MAPTTP53HPGDTSHRMEN1 | |
| SCHEMBL1515997 | 0.88 | GRM2 (0.53) | MAPTTP53HPGDTSHRMEN1 | |
| SCHEMBL1516115 | 0.88 | GRM2 (0.53) | MAPTTP53HPGDTSHRMEN1 | |
| SCHEMBL1516000 | 0.88 | GRM2 (0.53) | MAPTTP53HPGDTSHRMEN1 | |
| SCHEMBL3139586 | 0.84 | MEN1 (0.64) | MAPTTP53HPGDTSHRMEN1 | |
| SCHEMBL3148514 | 0.83 | GRM2 (0.53) | MAPTTP53HPGDTSHRMEN1 | |
| SCHEMBL7831157 | 0.81 | GRM2 (0.52) | MAPTTP53HPGDTSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137193-B1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2017-08-09 | — | — | EP | disclosed |
| US-8642603-B2 | Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof | SANOFI (FR) | 2014-02-04 | — | — | US | disclosed |
| US-20100075994-A1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2010-03-25 | — | — | US | disclosed |
| EP-0710658-B1 | 5-(Aryloxymethyl)oxazolines, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 2001-10-04 | — | — | EP | disclosed |
| EP-1077927-A1 | NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058495-A1 | NOVEL SUBSTITUTED CYCLIC COMPOUNDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ADIR ET COMPAGNIE (FR) | 1999-11-18 | — | — | WO | disclosed |
| EP-0710658-A1 | 5-(Aryloxymethyl)oxazolines, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1996-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075994-A1 | SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | GRM2, GRM1, GRIN2C | MAPT 1382/4885TP53 4885/4885HPGD 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.